Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Conclusion: Taken together, our data suggest that BAFF-R is amenable to CAR T-cell therapy and that targeting it may add to existing alternative strategies to overcome relapse from CD19 antigen loss, such as CD22 CAR T cells. Future strategies combining dual targeting of CD19 and BAFF-R may also be effective.DisclosuresWang: Mustang Therapeutics: Other: Licensing Agreement, Patents & Royalties, Research Funding. Forman: Mustang Therapeutics: Other: Licensing Agreement, Patents & Royalties, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Qin, H., Dong, Z., Wang, X., Cheng, W., Smith, D. L., Song, J. Y., Aldoss, I., Muschen, M., Forman, S. J., Kwak, L. W. Tags: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I Source Type: research